Ottawa, Ontario, Canada, July 2024 – Felicia R. has taken on the role of Director of Human Resources at Virica Biotech. With a wealth of experience in human resources management, Felicia is poised to drive HR strategies and initiatives to support the company’s continued growth and success.
Felicia R. has been with Virica Biotech for 2 years and 8 months. Prior to her current role, she served as the Manager of Human Resources & Corporate Compliance, where she was responsible for ensuring the safety, health, and happiness of Virica’s employees, as well as overseeing corporate compliance, developing and implementing SOPs, internal policies, and risk management.
Before joining Virica Biotech, Felicia worked as a Human Resources Manager at Bemac Collision Group, overseeing all aspects of HR functions across multiple locations in Ottawa and Gatineau. She also held a similar role at Jim Keay Ford Lincoln Sales Ltd., managing recruitment, performance appraisals, and employee pay plans.
Felicia’s earlier experience includes working as an Office Manager at All Seniors Care Living Centres and Indigo Park Canada, where she managed administrative teams and ensured smooth office operations. She also served as a Medical Office Manager at Pro Physio & Sport Medicine Centres, training new administrative staff and working with renowned sports medicine professionals.
Additionally, Felicia worked as an Administrator at Metroland Media Group, providing administrative support to the District Representative Team, and gained early experience as a Cooperative Education Student at Revera Inc..
Virica Biotech specializes in significantly increasing yields for cell and gene therapies and viral vaccines by addressing the innate antiviral defenses within production cells. The company’s unique panel of small molecules, known as Viral Sensitizers, turn off antiviral responses in cells, thereby boosting virus yields. Using an innovative high-throughput screening process, Virica identifies synergistic Viral Sensitizer molecules for various viruses or cell lines. These formulations are tailored to enhance virus yield in manufacturing facilities or improve the effects of viral therapies.
Read Also : The Power of Silence: How Leaders Can Harness the Art of Not Responding Immediately
